Introduction
The subject of enzymes has many facets, and the history is a long one because our forefathers from the most primitive times have used enzymes empirically to make bread, wine and cheese. For centuries, scientists have been puzzled and intrigued by the processes of putrefaction and fermentation. Serious investigation dates from the nineteenth century and originated in France, no doubt from the interest of that nation in winemaking and brewing. A landmark was the observation of the Baron Cagniard-Latour in 1836 that yeast is a living organism and, he correctly surmised, a plant. There arose two schools: one, headed by Pasteur, believed that fermentation could occur only in the presence of living organisms and the other, led by Berzelius and Liebig, took the view that fermentation was a mere chemical reaction. We now know that, in a sense, both were rightenzymes are proteins and can be made only by living cells, but the processes of fermentation obey the ordinary chemical laws. Another event of 1836 was the discovery of pepsin by Schwann. The next landmark was the discovery by Edouard Buchner in 1897 that if yeast is ground up with sand, the plant is killed, but the filtrate will still ferment sugar. He called the substance in the filtrate zymase, hence the suffix -ase used for all enzymes, except some of the old ones such as ptyalin, pepsin and trypsin. The term enzyme was introduced by Kiihne in 1878, and is merely Greek for 'in ye4st'.
In the twentieth century, many attempts have been made to determine the composition of enzymes. The first to be crystallized was urease, by Sumner in 1926, and Northrop crystallized trypsin and pepsin in 1930. The first enzyme to be analysed was ribonuclease in 1960.
The physiological study of enzymes has divided into two main streams, the study of the bodily secretions (saliva, gastric juice, pancreatic juice, &c.) and the study of intracellular enzymes, initiated by Embden and expanded by Meyerhof and Warburg. The complexities of intracellular metabolism may be illustrated by the oxidation of glucose, a simple substance chemically. If the chemist in his laboratory wishes to oxidize glucose he can simply apply a lighted match to it, but at 370 C and pH 7-2, the process requires about fifty steps, all mediated by enzymes.
The first applications of enzymology to clinical medicine were the estimation of enzymes in gastric juice, pancreatic juice and the urine, for example in acute pancreatitis. Although most of the advances in enzymology have been made by laboratory workers, it is right to record one great contribution by a clinician. Archibald Garrod published 'Inborn Errors of Metabolism' in 1909, and opened a new field in medicine. Now at least fifty diseases are known to be due to enzyme defects.
The first serum enzymes to be studied were the phosphatases, by the late Earl J King, and then the cholinesterases. Now numerous serum enzymes are being discovered and applied to clinical medicine. As a clinician I am well aware of how we grope in the dark -Sir Humphry Rolleston once described clinical medicine as 'blind man's bluff'. Those responsible for the care of patients are grateful to the pathologists and biochemists for their help in trying to make medicine more accurate.
For many years estimations of acid and alkaline phosphatase, of amylase and lipase, and of pseudocholinesterase, have had a valuable place in clinical biochemical investigation. In this country the development of the subject was largely due to the work of the late Professor E J King, whose untimely death has been an especial loss to enzymology.
Recently techniques have been developed for the measurement of the plasma activity of many more enzymes, in particular those concerned with known steps in intermediary metabolism, which are present in most cells. The most familiar of these enzymes is aspartate transaminase (glutamicoxaloacetic transaminase) and the contributions to this meeting will deal principally with these metabolic enzymes. Table I shows both the classical enzymes and most of the new metabolic enzymes that are now usually measuredand fresh tests are continually being introduced. The investigation and interpretation of changes in these metabolic enzymes in serum is one of the most rapidly expanding fields in clinical biochemistry to-day (King 1959) . Wilkinson (1962) has reviewed the whole field of clinical enzymology. through undamaged cell membranes. They leave the plasma by inactivation and catabolism in the general protein pool, and to a lesser extent by excretion into the bile or urine. This normal steady state of the passage of enzymes from cells to extracellular fluid will be altered if there is altered production of enzyme within the cells (whether occurring as an increase or a decrease), if there is obstruction to a normal pathway of enzyme secretion or excretion, or if there is a change in the cell permeability. Any damage to a cell which causes an increase in the permeability of the cell membrane, even without actual necrosis, will allow enzymes to escape at a greater rate. A rise in the concentration of enzymes in the extracellular fluid results, and this can usually be measured as an increase in enzyme activitycustomarily measured in serum rather than in plasma. An enzyme is measured not as its theoretical concentration (e.g. as vv,ug enzyme protein per litre of serum), but as its activity, this being -the rate at which it catalyses a particular chemical reaction (Bodansky 1959). The measured activity of an enzyme in serum is the result of many factors. It principally depends on the serum enzyme concentration, but in disease there may also be changes in inhibitors, activators, and required co-factors, though these have been little studied in relation to clinical problems. The results of serum enzyme determinations by different techniques will also often be markedly different (Thiers & Vallee 1958) . The serum enzyme concentration represents a balance between leakage of enzyme from the damaged cells, and loss of enzymes from the plasma into the general extracellular fluid to catabolism, or to excretion. Thus there is not necessarily a simple relationship between damage to the suspected tissue and changes in serum enzyme activity. In general, a rise in serum enzyme activity reflects an increased rate of cell damage rather than the total extent of cell damage. The intracellular enzymes have a wide distribution in the body, but are present in variable concentration in individual tissues (Fishman 1960) . Following tissue injury serum enzyme levels do not necessarily change in proportion to their activities in the damaged tissue (Hauss & Leppelmann 1958) . The increased permeability of the damaged cell membrane may effect the release of one enzyme more than another, and other factors such as differently altered rates of excretion may affect the serum levels. The discovery of isoenzymes, which are different molecular forms of the same enzyme, occurring in different proportions in different tissues (Wieland & Pfleiderer 1962) , sheds some light on this problem. An increase in the serum activity of any one enzyme is rarely diagnostic of damage to the cells of any one organ or tissue. Nevertheless, single or serial assays of the activity of a selected enzyme or enzymes may provide information as to the nature and extent of cell damage in three general types of clinical problem:
(1) If the differential diagnosis lies between a disease which is known to cause a particular pattern of serum enzyme change, and one that does notfor example, between myocardial infarction and pulmonary embolism.
(2) If a disease regularly causes serum enzyme changes, and it is required to know the rate or extent of cellular damage in the tissue known to be diseasedfor example, the degree of active hepatocellular damage in cirrhosis.
(3) If damage to a tissue is suspected which is so slight that it cannot be detected otherwisefor example, possible hepatotoxic effects of antidepressant drugs.
These are really the same criteria that apply for any type of biochemical investigation.
Enzyme Units
The nomenclature and measurement of enzymes has been confused. A recent international agreement (International Union of Biochemistry 1961) has allocated an index number, and a systematic and a trivial name, to all enzymes, and defined an enzyme unitbeing the activity which transforms one micromol of substrate per minute under optimum conditions and at a defined temperature. For clinical purposes in the future the official trivial name will come into use, and the enzyme activity be quoted as i.u./l. of serum, generally at 25°C. Table 2 shows the changes for name and normal range for some familiar enzymes (King & Campbell 1961) .
Enzymes in Liver Disease
Alkaline phosphatase: The alkaline phosphatases are a series of enzymes which hydrolyse organic phosphate monoesters, and are relatively nonspecific in substrate requirement. When estimated in serum, the normal range depends on the substrate employedin this country, using the King-Armstrong method, the normal range is 3-13 K.-A. units/100 ml.
Changes in serum alkaline phosphatase in liver disease have been studied for thirty years, and their diagnostic value well established. Yet the causes of these changes are still not fully understood (Gutman 1959) . In man the principal alkaline phosphatases arise from osteoblasts, and also from the parenchymal cells of the liver and from the intestine. Alkaline phosphatase is largely excreted in the bile. Any condition in which there is obstruction to biliary outflow, either intrahepatic or extrahepatic, causes an increase in the serum alkaline phosphatase because it is dammed back into the circulation. Any condition in which there is liver cell damage without biliary obstruction may cause a slight rise in serum alkaline phosphatase, and in this case the increase is probably derived from the liver cells. Serum alkaline phosphatase has been principally used to establish the degree of biliary obstructionand in more than 80% of cases this estimation, in conjunction with flocculation tests, has been successful in the differential diagnosis of obstructive jaundice from infective hepatitis. An increase in serum alkaline phosphatase greater than an increase in bilirubin is found when there are metastatic deposits in the liver.
As alkaline phosphatase increases in the serum in all instances of increased osteoblastic activity, there are times (for example in widespread metastatic carcinoma) when this estimation is of no definite value for establishing hepatic involvement. Studies of alkaline phosphatase isoenzymes may be of some help in these cases. Another enzyme, 5-nucleotidase, has been studied a little: it has more specific substrate requirements, for adenosine 5'-phosphate and similar compounds only. It appears to behave similarly to alkaline phosphatase in liver conditions, but not to become abnormal in bony conditions (Young 1958) . The proteolytic enzyme, leucine aminopeptidase, was introduced into clinical enzymology as a test for pancreatic disease, but has been found not to be valid for this purpose. Its increase in serum only occurs when there is intrahepatic or extrahepatic obstruction, and in this it has no advantages over alkaline phosphatase (Harkness et al. 1960 ).
Pseudocholinesterase: The two enzymes that hydrolyse acetylcholine are true cholinesterase, in erythrocytes and nervous tissue, and pseudocholinesterase which is widely distributed, is present in liver, and can be estimated in serum. At one time this estimation enjoyed great popularity in the investigation of liver disease (McArdle 1940) . Serum pseudocholinesterase is decreased, in parallel with the serum albumin, when there is parenchymal liver cell damage and gives little more additional information. It is normal in uncomplicated obstructive jaundice. Nevertheless, this estimation is important in two other conditions: it can be used as a measure of poisoning by organophosphorous insecticides (which are anticholinesterases), and to investigate familial sensitivity to suxamethonium.
Metabolic Enzymes
The introduction of studies of the metabolic enzymes has added a new and extremely valuable tool to the investigation of liver disease. Here we have a measure of the rate of liver cell damage itself, and not of obstruction (as with alkaline phosphatase), of y-globulin response to injury (as with the flocculation reactions), of hepatic clearance (as with the sulphobromophthalein test), or of total healthy liver cell mass (as with the serum albumin).
Most of these enzymes behave in a similar fashion in liver diseaseaspartate transaminase, alanine transaminase, and isocitrate dehydrogenase being the enzymes most commonly studied. Lactate dehydrogenase changes little in liver disease and is not used for this purpose. Aldolase is relatively insensitive and is not found valuable. Claims have been made for greater specificity for other enzymes, in particular ornithine carbamyl transferase (Reichard 1961) , and sorbitol dehydrogenase (Wuest & Schoen 1961) , but these estimations have not come into general use.
Aspartate transaminase (AsT): This enzyme, formerly known as glutamic-oxaloacetic transaminase, is present in highest concentrations in cardiac muscle and in liver, and increases in the serum after myocardial infarction and hepato-cellular damage. It is in consequence the most widely used serum enzyme. The normal range is 5-17 i.u./l. at 250 C. The experiences of most workers in the field on the value of aspartate transaminase estimations are similar (Wroblewski 1958).
Infective hepatitis: The serum AsT in infective hepatitis begins to rise above normal during the prodromal period, usually a few days before the onset of jaundice. It reaches a peak of 250-1,000 i.u./l. corresponding to the time of maximum illness, and falls to normal about two weeks after the onset. If the level fails to fall, this suggests possible development of chronic liver disease and the patient should be kept in bed. Clinical relapse is associated with a second rise in serum AsT. Serial estimations are therefore important.
During epidemics of non-icteric hepatitis the serum AsT may be 50-100 i.u./l. at the time of maximum illness.
Infectious mononucleosis: The serum AsT is usually raised at some time in the course of the illness, but rarely above 150 units. Higher values are found when there is obvious hepatitis.
Acute hepatic necrosis: The serum AsT may rise to very high levels, occasionally above 5,000 i.u./l. in all forms of acute hepatic necrosis, as most of the enzyme content of the liver is rapidly discharged into the plasma. Minimal hepatocellular damage, due to a great variety of drugs, may be detected by slight rises in the serum AsT before there is any clinical or other biochemical evidence of liver damage. If the serum AsT rises above 20 i.u./l. and continues to rise when the patient is receiving, for example, iproniazid, then treatment must be stopped.
Cirrhosis: The serum AsT will rise in portal or biliary cirrhosis when there is active hepatocellular damage. The level usually rises to between 25 and 150 i.u./l. depending on the degree of activity, and is unrelated to coma or compensation. If the disease is inactive, a normal value will be found. In a flare-up the enzyme pattern of acute hepatitis will be found.
Malignant disease: The serum AsT is moderately raised, up to about 150 i.u./l., in about two-thirds of the cases of primary or secondary hepatic carcinoma. The level depends on the rate of destruction of liver cells by the growth. Localized or metastatic malignant disease elsewhere in the body does not affect the serum AsT.
Obstructive jaundice: The serum AsT is generally moderately raised in extrahepatic obstructive jaundice, the enzyme increment being possibly due to obstruction and partly secondary to hepatocellular damage. The level rarely exceeds 150 i.u./l. After relief of the obstruction, the level returns to normal in about a week. In cholecystitis, uncomplicated by either obstruction or cholangitis, the serum AsT remains normal. Secondary liver disease: In severe or prolonged congestive heart failure the serum AsT rises due to centrilobular hepatic necrosis. As the heart failure may be due to an infarction which has itself raised the AsT, such conditions may be difficult to sort out. The same difficulty applies in the detection of minor hepatic necrosis due to nicoumalone, when this possibly hepatoxic anticoagulant is being given to a patient after a myocardial infarction.
Alanine transaminase (AlT): This enzyme, formerly known as glutamic-pyruvic transaminase, is present in highest concentration in liver, and principally increases in the serum in cases of hepatocellular damage. The normal range is 4-13 i.u./l. at 250 C. Generally the serum AlT behaves in the same way as the serum AsT in various types of liver disease (Wroblewski 1958) . In most circumstances the serum AlT is altered slightly less than the AsT. This difference appears to be most consistent in cirrhosis and when there is carcinoma in the liver. On the other hand, in virus hepatitis the serum AlT may be raised slightly more than the serum AsT.
Some have considered that calculation of the AsT/AlT ratio is valuable in sorting out obscure cases of liver disease, but this is probably not so. The disadvantage of the AsT relative to the AlT is that it is generally less sensitive, and there is also the technical point that it is somewhat less stable in stored serum. The advantage of the AIT is that it does not increase significantly in serum after myocardial infarction, hence it is valuable in the mixed cardiac and hepatic cellular damage cases referred to above.
Isocitrate dehydrogenase (ICD): This enzyme is present in high concentration in both liver and cardiac muscle; its serum activity increases as a result of hepatocellular damage but not after myocardial infarction, unless there is secondary liver damage due to congestive failure. The normal range is 1-3 5 i.u./l. at 250 C. In general the pattern of response of serum ICD in liver disease is the same as that of the transaminases (Bell et al. 1962) . Special points are that in infectious mononucleosis the serum ICD is always raised at some stage during the disease, and that the test seems very sensitive to liver damage due to drugs. The serum ICD is almost always normal in extrahepatic obstructive jaundice (in contrast to the intrahepatic obstruction of biliary cirrhosis) unless there is secondary liver damage.
The particular advantage of ICD over the transaminases is this normality in obstructive jaundice. The estimation is more expensive, because the enzyme reaction requires the costly nicotinamide-adenine dinucleotide phosphate.
Conclusion
At present two different types of enzyme assay are necessary for the investigation of liver disease.
Alkaline phosphatase serves to measure biliary obstruction, though moderate increases are found in other types of liver disease. One of the metabolic enzymes serves to measure the rate of hepatocellular damage, particularly in assessing the activity of chronic liver disease and in detecting damage due to drugs.
